Filing Flows › Mangoceuticals (MGRX) › Q4 2024
Mangoceuticals (MGRX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 20, 2025
Mangoceuticals (MGRX) reported revenue of $105K for the fourth quarter 2024 (Q4 2024), -57% from a year earlier and -21% from the quarter before.
Mangoceuticals, Q4 2024: revenue $105K (-57% year over year), net loss $1.9M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $105K | -21% | -57% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$1.9M | — | — |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $105K in Q4 2024, down 57% year over year and down 21% from the previous quarter.
Gross margin was 76.1%, up 17.8 points from a year earlier. Operating costs exceeded revenue by $1.7M, an operating margin of -1594.0%. Operating expenses fell 35% while revenue fell 57%. The quarter ended with a net loss of $1.9M, narrower than the previous quarter's $2.0M loss. Minority interests bore $0K of it: to shareholders the quarter was a loss of $1.9M.
Operating cash flow was −$1.1M. Non-cash charges added back $729K of depreciation and amortization and $51K of share-based compensation.
Questions
What was Mangoceuticals' revenue in the fourth quarter 2024?
Mangoceuticals (MGRX) reported revenue of $105K for the fourth quarter 2024 (Q4 2024), -57% from a year earlier and -21% from the quarter before.
Source: Mangoceuticals 10-K on SEC EDGAR.